
CTI BioPharma Corp (AKA: Cell Therapeutics Inc) Profile last edited on: 10/19/2023
CAGE: 37GC6
UEI: H4GBVP9DGRL6
Business Identifier: NO Business Identifier is currently available for this company. Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
3101 Western Avenue Suite 600
Seattle, WA 98121
Seattle, WA 98121
(206) 282-7100 |
busdev@ctiseattle.com |
www.ctibiopharma.com |
Location: Multiple
Congr. District: 07
County: King
Congr. District: 07
County: King
Public Profile
CTI BioPharma Corp, formerly Cell Therapeutics Inc, develops, acquires and commercializes novel treatments for cancer. The Company's lead product is called arsenic trioxide (Trisenox), which was acquired in January 2000. Trisenox is marketed for patients with a type of blood cell cancer, called acute promyelocytic leukemia, who have relapsed or failed standard therapies. The Company is also developing a new way to deliver cancer drugs more selectively to tumor tissue in order to reduce the toxic side effects and improve the anti-tumor activity of existing chemotherapy agents. In addition, the Company has identified a novel drug target, lysophosphatidic acid acyltransferase (LPAAT-Ã) that, when inhibited, has been shown to reduce tumor cell growth in preclinical models. Cell Therapeutics, Inc. is developing pixantrone, a Phase III single-agent clinical trial product for the treatment of non-Hodgkin's lymphoma and various other hematologic malignancies, solid tumors, and immunological disorders; OPAXIO, a Phase III clinical trial product for the treatment of ovarian, esophageal, and non-small cell lung cancer; and brostallicin, a Phase I/II clinical trials product for the treatment of sarcoma. The company has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
100-149Revenue Range
10M-15MVC funded?
YesPublic/Private
Publicly TradedStock Info
NASDAQ : CTICIP Holdings
150-249Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2000 | 2 | NIH | $550,000 | |
Project Title: Phosphatidic Acid Inhibitors Effect on EAE |
Key People / Management
James Bianco -- President
Kenny Rankin
Kenny Rankin